Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. “Equillium first set out to acquire Metacrine in an all-stock transaction in early 2022, with the intent of adding cash runway in a very difficult financing market,” said Bruce Steel, chief executive officer of Equillium. “However, our recent strategic partnership with Ono Pharmaceutical is expected to extend our ca
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks